Remitting multiple sclerosis: Natalizumab reduces relapses and disability

Taking the new generation anti-inflammatory drug natalizumab for two years lowers the number of remitting multiple sclerosis patients who experience relapses and progression of disability. This is the main finding of a systematic review published in the latest edition of The Cochrane Library.

Read the whole article on Physorg

More from Physorg